Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CombiMatrix to Meet with FDA.


NEWPORT BEACH, Calif. -- Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG ACTG Acting
ACTG AIDS Clinical Trial Group
ACTG Actuating/Actuator
) announced today that its CombiMatrix group has received a letter from the Office of In Vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment.

in vi·tro
adj.
In an artificial environment outside a living organism.
 Diagnostic Device Evaluation and Safety (OIVD OIVD Office of In Vitro Diagnostic Device Evaluation & Safety (US FDA) ) of the US Food and Drug Administration (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
). The letter invites the company to meet with the OIVD to discuss CombiMatrix Molecular Diagnostics' (CMDX) plans to market its Constitutional Genetic Array Test (CGAT CGAT Canadian Genome Analysis and Technology
CGAT Coast Guard Acceptance Team
) in September. The company plans to meet with the FDA in the near future.

"We are pleased to have the opportunity to meet with the FDA to present our technology and our services," said Dr. Amit Kumar, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of CombiMatrix and Chairman of CMDX.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 46 patent portfolios, which include U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud Credit card fraud is a wide-ranging term for theft and fraud committed using a credit card or any similar payment mechanism as a fraudulent source of funds in a transaction. The purpose may be to obtain goods without paying, or to obtain unauthorized funds from an account.  protection, database management, data encryption & product activation, digital media transmission (DMT See DSL. (R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS See eComStation. , interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 25, 2006
Words:520
Previous Article:Biophan Forms Scientific Advisory Board for MYOTECH; Top Cardiologist and Cardio-Thoracic Surgeons Join Advisory Board to Support Development of the...
Next Article:Fisher Scientific Reports Record Quarterly Financial Results; Company Announces Second-Quarter Adjusted EPS of $1.10.



Related Articles
Acacia Research Sets Revised Date for Special Meeting to Vote On Merger and Recapitalization.
CombiMatrix Names Colonel, ret., Dr. David L. Danley Director, Homeland Security and Defense Programs.
CombiMatrix and Novavax to Collaborate on Technology for Influenza Vaccine.
CombiMatrix Molecular Diagnostics to Test for Influenza; Service Will Enable Identification of (H5N1) Bird Flu.
CombiMatrix Launches Next Generation of Its Influenza A Surveillance Technology; 4X2K(TM) Format for All Strains of Influenza A, Including the H5N1...
CombiMatrix Launches ElectraSense(TM) Influenza Surveillance System.
CombiMatrix Awarded Additional $1.9 Million Military Contract from the Army Research Office; New Contract an Addition to Existing CombiMatrix...
CombiMatrix and Furuno Launch DNA Microarray Synthesizer; New CE Marked Instrument Incorporates Reagents and Arrays in a Single Stand-Alone Unit.
Acacia Research Reports Third Quarter Financial Results.
FDA Provides Positive Opinion on the Regulatory Status of CombiMatrix's First Array-Based Molecular Diagnostic.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles